BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Wendy Huang

Session 7 – Sharing Biotech Successes-Taiwan BIO Awardee Showcase

Date:27 July (Thursday)
Time:10:40 – 12:10 (GMT+8)

Wendy Huang


Dr. Wendy Huang is the President and President of the Board of AnnJi Pharmaceutical Co., an R&D based, clinical stage new drug company dedicated to the development of first-in-class small molecules, for the treatment of neurological, dermatological and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis (IPF) and Kennedy’s Diseases (also known as Spinal and Bulbar Muscular Atrophy, or SBMA). Under her leadership since 2019, AnnJi team has advanced several development projects and built an award-winning portfolio,

Prior to Joining AnnJi in 2019, she was President and CEO of Lumosa Therapeutics since 2013, where Dr. Huang established a reSeaerch and Development (rSD) business model and focused on the translation and development of novel drugs in pain management and stroke treatment. Naldebain®, the first week-long acting analgesic IM injection, was approved by Taiwan FDA in March 2016. Dr. Huang took Lumosa to public in September 2016 (TpEX6535).
Before returning to Taiwan in 2013, Dr. Huang held several executive positions in several global pharmaceutical companies, including VP of Dermatology Discovery Unit and Medicine Development Lead in GSK, Sr. VP of Global Research and Nonclinical Development in Stiefel Laboratories, and VP of research & Preclinical Development and Head of Center for Skin Biology in Connetics Corp.
Dr. Huang’s over 40 years pharmaceutical career covers multiple therapeutic areas, medical devices and cosmetic products and crossed a broad spectrum of technical functions; including Drug Discovery, Safety Assessment, DMPK, Pharmaceutical Development, Quality Assurance, and Regulatory Affairs. She has a strong track record in global product development and R&D management, including successful market authorization of a dozen or so of new drug products and devices, as well as the building/rebuilding of 5 R&D departments through 3 M&A’s and 2 company relocations. Dr. Huang also participated in due diligence and negotiation of many successful in-licensing, partnering and acquisition deals.
Dr. Huang received her BS in Pharmacy from National Taiwan University and her PhD in Toxicology from North Carolina State University.

Company Profile

Founded in 2014, AnnJi Pharmaceutical Co., Ltd. (AnnJi) is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy)

Our mission is to develop innovative therapeutics to improve the quality of life of patients with neglected diseases. Our goals are to translate and develop unique, innovative, and highly differentiated drug therapies and to engage global collaborators and business partners in late-stage product development and commercialization.

The choices of therapeutic targets are mechanistically driven based on:

1.Androgen Receptor Degradation Enhancer (ARDE) for the treatment of skin disorders

2.Nrf2 Activator for PolyQ neurodegenerative diseases

3.Histone Deacetylase 6 Inhibitor (HDAC6i) for peripheral neuropathy and fibrotic diseases AnnJi’s current leading pipelines target several unmet medical needs:

Clinical Stage: 

AJ201 is a Phase I completed asset for rare polyglutamine (polyQ) diseases, such as Kennedy’s disease (spinal and bulbar muscular atrophy, SBMA) and Huntington’s disease (HD); 

IND-enabling Stage:
AJ302 for chemotherapy-induced peripheral neuropathy (CIPN) and AJ202 for androgenetic alopecia (AGA).